Open House Originale rebate agreements for Dapagliflozin
Oryginalny tytuł ogłoszenia
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-07 - Dapagliflozin
Ocena szansy
Skąd ta ocena?
Szansa
56 / 100
Złożoność
48 / 100
Czynniki ryzyka
Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...
Only pharmaceutical entrepreneurs meeting the AMG and authorisation conditions may participate.
Submission deadline in 4 days
Głęboka analiza portfolio
Wykorzystuje:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Przegląd
Moderate opportunityKluczowe fakty
- Supplies contract
- 1 lot
- Duration until Aug 2026
- Conclusion of rebate agreements for the medicinal product Dapagliflozin under Section 130c SGB V.
- Uniform Open House terms apply; no individual negotiation of contract content.
Pokaż pełne podsumowanie
Open House supply arrangement for Dapagliflozin pharmaceutical products in Germany, led by Techniker Krankenkasse with participating sickness funds. It is not a classic public procurement award procedure; contracts are concluded on uniform terms with all eligible pharmaceutical companies that meet the stated conditions. No contract value is stated. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and documents are only provided electronically to eligible companies.
Ryzyka
Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...
Only pharmaceutical entrepreneurs meeting the AMG and authorisation conditions may participate.
Submission deadline in 4 days
Analiza może być niepełna
Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.
Kluczowe wymagania
Technical
- Applicant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the relevant medicinal product.
- Applicant must have its seat in the scope of the AMG, another EU Member State, or another EEA state.
- Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.
Kryteria udzielenia
Lot 1
Zamawiający
Lokalizacja
Hamburg, DEU
Strona
Identyfikator
992-80116-93
Działalność
Health
Części (1)
LOT-0001
Open House Originale rebate agreements for Dapagliflozin
Open House contract for rebate agreements under Section 130c SGB V for the active substance Dapagliflozin. Scope is nationwide in Germany. The lot information comes from structured data and the notice text. No lot value is stated. The procedure is open to eligible pharmaceutical companies during the contract period.
Lokalizacja
Czas trwania
Kategoria
Kryteria udzielenia
Termin
Szczegóły kryteriów
Participation and suitability requirements in the Open House procedure
Uwaga do wartości
Pokaż oryginalne dane TED
Oryginalny tytuł części
Open House Originale Rabattverträge 2024-07 - Dapagliflozin
Oryginalny opis TED
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c SGB V zum Wirkstoff Dapagliflozin zu schließen.
Szczegóły zamówienia
- Data publikacji
- 19 Jul 2024
- Języki
- German
Metadane referencyjne
- Podstawa prawna
- 32014L0024
Identyfikatory referencyjne
- ID przetargu
- 434034-2024
Dokumenty (1)
Podobne przetargi
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Ocena szansy
Skąd ta ocena?
Szansa
56 / 100
Złożoność
48 / 100
Czynniki ryzyka
Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...
Only pharmaceutical entrepreneurs meeting the AMG and authorisation conditions may participate.
Submission deadline in 4 days
Głęboka analiza portfolio
Wykorzystuje:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications